12月15日 - ** 万达制药VNDA.O股价上涨7.2% ，至6.74美元
** 该公司提交了 (link) 生物制剂许可申请(BLA) imsidolimab 用于治疗泛发性脓疱型银屑病$(GPP)$，这是一种罕见的、危及生命的炎症性皮肤病。
** 晚期GEMINI-1和GEMINI-2试验的积极数据支持BLA的申请，这些数据显示该药物具有快速、持续的疾病清除能力和良好的安全性。
** 万达以GPP是一种罕见的孤儿病，有大量需求未得到满足为由，请求FDA优先审查；称FDA可能最早于2026年中期批准该项目
** 截至上次收盘，VNDA股价年累计上涨30
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.